Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 6/20 | 0.42 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.42 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MDK | P21741 | 2/20 | 0.38 |
| ▸ | BDNF | P23560 | 2/20 | 0.38 |
| ▸ | PTN | P21246 | 1/20 | 0.38 |
| ▸ | FGF1 | P05230 | 1/20 | 0.38 |
| ▸ | CD69 | Q07108 | 1/20 | 0.38 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.36 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.36 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16269841 | 1.00 | LGALS3 (0.42) | LGALS3LGALS8LGALS4MAPK1ALDH1A1 | |
| SCHEMBL21316642 | 1.00 | LGALS3 (0.42) | LGALS3LGALS8LGALS4MAPK1ALDH1A1 | |
| SCHEMBL22472735 | 1.00 | LGALS3 (0.42) | LGALS3LGALS8LGALS4MAPK1ALDH1A1 | |
| SCHEMBL12580409 | 0.94 | LGALS3 (0.40) | LGALS3LGALS8LGALS4MAPK1ALDH1A1 | |
| SCHEMBL20290392 | 0.93 | LGALS3 (0.42) | LGALS3LGALS8LGALS4MAPK1ALDH1A1 | |
| SCHEMBL19928682 | 0.93 | LGALS3 (0.42) | LGALS3LGALS8LGALS4MAPK1ALDH1A1 | |
| SCHEMBL18737220 | 0.93 | LGALS3 (0.42) | LGALS3LGALS8LGALS4MAPK1ALDH1A1 | |
| SCHEMBL24121225 | 0.92 | LGALS3 (0.39) | LGALS3LGALS8LGALS4MAPK1ALDH1A1 | |
| SCHEMBL18936352 | 0.90 | LGALS3 (0.43) | LGALS3LGALS8LGALS4MAPK1ALDH1A1 | |
| SCHEMBL19325099 | 0.90 | LGALS3 (0.43) | LGALS3LGALS8LGALS4MAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210187166-A1 | MIXTURE OF POLYMERS, LUBRICATING FLUID AND POROUS MATERIALS COMPRISING SAID MIXTURE, AND SURFACE BEARING SAID MIXTURE | CENTRE HOSPITALIER UNIVERSITAIRE SAINTE-JUSTINE (CA) | 2021-06-24 | — | — | US | disclosed |
| US-20200214564-A1 | Mixed Ionic Electronic Conductors: Devices, Systems and Methods of Use | BATTELLE MEMORIAL INSTITUTE | 2020-07-09 | — | — | US | disclosed |
| US-10660906-B2 | Hyaluronan conjugates with pharmaceutically active substances, methods and compositions | SYNARTRO AB (SE) | 2020-05-26 | — | — | US | disclosed |
| US-10398636-B2 | Deuterium-enriched hyaluronan | Deuteria Biomaterials (US) | 2019-09-03 | — | — | US | disclosed |
| US-9962565-B2 | Optically-activated system for reducing the appearance of skin imperfections | ELC MANAGEMENT LLC (US) | 2018-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10398636-B2 | Deuterium-enriched hyaluronan | DOHH, CD44, HDHD5 | LGALS3 521/4885LGALS8 658/4885LGALS4 424/4885 |
| US-10660906-B2 | Hyaluronan conjugates with pharmaceutically active substances, methods and compositions | CD44, PIGS, HPSE | LGALS3 416/4885LGALS8 374/4885LGALS4 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.